Inventor · disambiguated record
Keiko Esaki
Also filed as: ESAKI KEIKO
3 granted patents·9 pending applications·59 citations·filing 2001–2024
74Inventor score
Top patents by PatentIndex Score
12 records- 0193US8575317B2Anti-NR10 antibody and use thereofKURAMOCHI TAICHI·Filed 2009·Granted Nov 5, 2013·37 cites·14 claims
- 0291US9399680B2Nucleic acids encoding anti-NR10 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Jul 26, 2016·17 cites·37 claims
- 0388US2024294653A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 0482US2023183363A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0579US9556264B2Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredientCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Jan 31, 2017·5 cites·25 claims
- 0668US2020002429A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 0766US2011129459A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2008·Application pending·0 cites
- 0863US2015175704A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Application pending·0 cites
- 0946US2007238128A9Method for screening substances capable of promoting oligomerization of receptor protein moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2004·Application pending·0 cites
- 1043US2017129950A1Humanized Anti-Epiregulin Antibody, and Cancer Therapeutic Agent Comprising Said Antibody as Active IngredientCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Application pending·0 cites
- 1143US2005084908A1Methods for detecting binding of low-molecular-weight compound and its binding partner moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2004·Application pending·0 cites
- 1237US2003138870A1Method of evaluating binding activity of ligand to lignad-binding proteinFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Keiko Esaki files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →